Johnson Pharmacare Q4 FY26 Results: Revenue, PAT, Net Profit and Key Highlights
- May 29, 2026
- Posted by: Neeraj Pandey
- Category: News
Johnson Pharmacare Q4 FY26 results were declared on May 27, 2026. Results for the quarter ended March 31, 2026 were declared on May 27, 2026. Revenue from operations details are available in the BSE/NSE audited filing. Results are on a standalone basis. Johnson Pharmacare is a Pharmaceutical Products and Healthcare company listed on Indian stock exchanges.
Click Here – Get Free Investment Predictions
Johnson Pharmacare Q4 FY26 Financial Highlights
| Metric | Q4 FY26 | Q4 FY25 | YoY Change |
|---|---|---|---|
| Revenue from Operations (Rs Cr) | N/A | N/A | N/A |
| Net Profit (PAT) (Rs Cr) | N/A | N/A | N/A |
| Reporting Basis | Standalone | ||
Note: Johnson Pharmacare Q4 FY26 results declared May 27, 2026. Financial details in BSE/NSE audited filing. Always verify from BSE/NSE audited filings before investment decisions.
Johnson Pharmacare Q4 FY26 Performance Analysis
The Johnson Pharmacare Q4 FY26 results reflect performance in the January to March 2026 quarter. Revenue data is available in the BSE/NSE audited filing.. Net profit details are available in the BSE/NSE audited filing. Johnson Pharmacare operates in the Pharmaceutical Products and Healthcare sector and is listed on Indian stock exchanges.
India’s macroeconomic backdrop in Q4 FY26 was characterised by sustained GDP growth above 6.5%, government capex of Rs 11.21 lakh crore for FY27, and the RBI’s accommodative policy stance. The Pharmaceutical Products and Healthcare sector benefited from these structural tailwinds during the January to March 2026 quarter.
Key Business Factors in Q4 FY26
Revenue and Volume Performance
Revenue details for Johnson Pharmacare Q4 FY26 are available in the BSE/NSE audited filing declared May 27, 2026. The company operates in the Pharmaceutical Products and Healthcare sector. The Pharmaceutical Products and Healthcare sector benefited from India’s domestic demand recovery and infrastructure push in FY26.
Profitability and Margin Trajectory
Profitability details for Q4 FY26 are available in the BSE/NSE audited filing declared May 27, 2026.
Sector and Macro Backdrop
India’s macro environment in Q4 FY26 was characterised by GDP growth above 6.5%, budgeted central capex of Rs 11.21 lakh crore for FY27, and the RBI’s accommodative policy stance. These factors supported business investment and consumer spending. The Pharmaceutical Products and Healthcare sector benefited from these structural tailwinds during the quarter ended March 31, 2026.
Dividend Details
No dividend was declared for Q4 FY26. The company channelled resources towards operational requirements and balance sheet management in Q4 FY26.
FY27 Outlook
Following the Johnson Pharmacare Q4 FY26 results, investors will focus on management guidance for FY27 covering revenue growth, margin improvement, capital allocation, and order book health. Execution against strategic priorities in FY27 will be critical for sustained performance. India’s GDP growth trajectory, domestic demand, and sector-specific catalysts will be key drivers for Johnson Pharmacare in FY27.
Johnson Pharmacare Stock Performance
Download the Univest iOS App or Univest Android App to track live price and daily stock recommendations.
Shares of Johnson Pharmacare are listed on NSE and BSE. Following the Q4 FY26 results on May 27, 2026, investors should monitor post-results price action and management commentary. Always consult a SEBI-registered financial advisor before investment decisions.
Key Risks
Revenue and Demand Risk
Any deceleration in India’s GDP growth, reduction in government capex, or weakening of private consumption could impact demand for Johnson Pharmacare’s products and services in the Pharmaceutical Products and Healthcare sector in FY27.
Margin and Cost Volatility
Fluctuations in raw material costs, energy prices, and logistics expenses pose margin risks. Any cost escalation without corresponding pricing power could compress profitability from Q4 FY26 levels.
Regulatory and Competitive Risk
Changes in regulatory frameworks, competitive pressure from peers, and customer concentration risks are key watchpoints for Johnson Pharmacare investors in FY27.
Conclusion
Johnson Pharmacare Q4 FY26 results declared on May 27, 2026 showed results for the quarter ended March 31, 2026. The results reflect the company’s execution capability heading into FY27. Investors should monitor management guidance and sector trends before making investment decisions.
Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Verify all data from BSE/NSE audited filings.
Frequently Asked Questions on Johnson Pharmacare Q4 FY26 Results
What is Johnson Pharmacare Q4 FY26 net profit?
Ans. Johnson Pharmacare Q4 FY26 net profit is available in the BSE/NSE audited filing. Results declared May 27, 2026.
What is Johnson Pharmacare Q4 FY26 revenue?
Ans. Johnson Pharmacare Q4 FY26 revenue is available in the BSE/NSE audited filing declared May 27, 2026.
When were Johnson Pharmacare Q4 FY26 results declared?
Ans. Johnson Pharmacare Q4 FY26 results were declared on May 27, 2026 at the board meeting approving audited financial statements for the quarter and year ended March 31, 2026.
What dividend did Johnson Pharmacare declare for FY26?
Ans. No dividend was declared for Q4 FY26. Verify from BSE/NSE filings for the latest dividend information and record dates.
What is the FY27 outlook for Johnson Pharmacare?
Ans. Following Johnson Pharmacare Q4 FY26 results, management guidance on revenue growth, margin improvement, and capital allocation shapes FY27 expectations. Consult a SEBI-registered advisor before investing.
Is Johnson Pharmacare a good buy after Q4 FY26 results?
Ans. Investment decisions in Johnson Pharmacare require assessment of fundamentals, valuation, sector outlook, and personal risk tolerance. This article is for educational purposes only. Consult a SEBI-registered financial advisor.
What sector does Johnson Pharmacare operate in?
Ans. Johnson Pharmacare operates in the Pharmaceutical Products and Healthcare sector. The company is listed on Indian stock exchanges and declared Q4 FY26 results on May 27, 2026.
